The case for & against
Bull & Bear analysis
Bearish
Tempest Therapeutics (NASDAQ: TPST) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer through advanced therapies such as CAR-T. The firm remains at the forefront of immunotherapy advancements, positioning itself within the rising theme of targeted cancer therapies. However, its valuation and operational execution have faced significant headwinds, particularly a dramatic decline in stock price over the last year, making investors cautious about its financial stability and development pace.
Bull says
- ↑100% complete response in 15 efficacy-evaluable patients for TPST-2003 shows strong efficacy.
- ↑Secured up to $50M via Lincoln Park stock purchase agreement to fund trials.
- ↑Analyst consensus near $11 target implies ~873% upside from current levels.
- ↑Average price target ~$2.92 suggests room for rebound from $1.07 share price.
- ↑High growth factor indicates robust future revenue potential in CAR-T.
- ↑Moderate debt levels and favorable momentum could attract risk-tolerant investors.
Bear says
- ↓Q2 2026 net loss of $5.2M and YTD loss of $32.9M highlight severe cash burn.
- ↓Only $0.8M cash on hand pressures funding for ongoing trials.
- ↓Shareholders’ equity deficit of $1.1M raises going-concern and dilution risks.
- ↓Negative analyst revisions and high short interest reflect weakening sentiment.
- ↓Low institutional ownership underscores lack of confidence and limited liquidity.
- ↓Weak profitability and negative earnings yield signal operational inefficiencies.